Agenus Inc., a biotechnology company, develops and commercializes immunotherapies for cancer and infectious diseases. It markets Oncophage vaccine for the treatment of adjuvant renal cell carcinoma (kidney cancer). The company also has various product candidates under development, which include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of non-small cell lung cancer, melanoma, malaria, and singles, as well as in Phase II clinical trials for the treatment of Alzheimer's disease. In addition, the company's product candidates under development comprise Prophage, which is in Phase II clinical trials for the treatment of glioma (brain cancer) and pediatric neurological tumors; and HerpV, which is in Phase I clinical trials for the treatment of genital herpes. Further, it has various other undisclosed vaccines in Phase I and II studies. The company was formerly known as Antigenics Inc. and changed its name in January, 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.